Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
about
DNA gyrase, topoisomerase IV, and the 4-quinolonesActivity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitroMechanism of differential activities of ofloxacin enantiomersBesifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial InfectionsEffect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureusEfficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistanceIn vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungiDual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniaeEfflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatisFluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosityCloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IVA mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase IIMultiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.Assignment of functional amino acids around the active site of human DNA topoisomerase IIalpha.Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitroIdentification of novel mutation patterns in the parC gene of ciprofloxacin-resistant isolates of Neisseria gonorrhoeae.Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococciTopoisomerase IV is a target of quinolones in Escherichia coliDNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.Challenges of antibacterial discoveryNovel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolatesThe 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus.Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacinIntroduction of a norA promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration.Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin.Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesisCloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
P2860
Q24643546-B5648DB3-F81B-43B2-A0F4-5328D51249C1Q24673222-B2E5C3D2-0421-451C-BA93-90264F206CFCQ24675769-DEB241C4-B0D5-4240-B7E4-01EC3F52228CQ26752242-544B4E70-C48A-4138-8629-614233B0F91EQ28343420-8E68733F-D6B0-4E3F-A52F-EB1A3529708FQ28361569-87CC037E-9D54-445E-BD34-35445056F7F9Q28367448-7913B080-BD4C-4817-959C-5828A187D90CQ28377381-1A1D69F8-A319-43DF-AB44-95CDD6CF4911Q28378761-CB2A84E5-1F12-4D95-86F5-BB2EDB301779Q28379135-7C7883A0-E627-416A-925A-A6C53E3B279EQ28492734-20E98D78-9DED-4902-9C31-E8C26970E345Q30448695-749AD7C6-A783-4225-AB05-129407BF05D5Q30784091-AC32CCAA-3D5D-4284-8E52-F4E12AE355E8Q30870346-DF4593ED-CC13-413A-9EDD-5DDD426FE826Q33690598-1BA2FAFB-89F5-4AA4-B749-45E58B84B8DEQ33690765-47F93BB3-BAD1-435E-80A4-9D1BADD613D7Q33694924-FE7ED43A-37B4-4CBB-BDC0-6156CFF0C643Q33695982-98EE0142-81AA-47DC-AD4E-FD8DE969604CQ33696363-5EC804D0-4C67-44C0-97C7-DCDBE8F47287Q33696730-3196695A-9F38-4516-B5F4-237364895780Q33698167-6407547C-A9AE-445C-8B1A-883EA458A5A2Q33698247-E7117D69-09E5-4B94-928B-DB9709D0C7ACQ33700561-6719C991-2BDD-436B-8A89-FBD7C5EBB86DQ33724600-3EE28097-F552-4484-8D09-977369FBA068Q33740527-D9BB43D7-FAAA-487A-9A18-79FD8922F1DFQ33793074-4292185C-181C-4568-8E75-0DE5B3934E81Q33836603-78BC1B4E-202B-4660-B300-9E920D047D1FQ33947205-83A94904-7224-4A73-82B8-2B2EA485CF7FQ33976037-D0C3C31A-FB8F-437E-9AB2-F99AD2C2B8D6Q33976079-BDAD40B1-1BD5-4944-AB4D-74D6AF52CBEAQ33976753-B4D1AFBC-F6BE-4673-8993-1948A7854131Q33976799-06990FFE-B3DD-4989-A2E7-E0E70254ACC1Q33977109-2D6FD33A-B167-430C-8DDE-37ABA6EA706DQ33977640-908A6B80-ED77-414F-9000-BF0E03BD1ED6Q33979593-2B47DE7C-DE05-4C31-ADE1-AF137A563EEBQ33980255-702CF2CF-D8D6-4DFB-9CE8-A719E7A1F63CQ33980747-8BA753D7-23BA-4CA9-ACF2-017FE251278BQ33981750-3F8BC003-B089-489F-9BC4-8152E17E7145Q33983092-09417DE6-0513-4049-9450-7E65171F9AB3Q33983660-09712A3E-52D6-4117-A10D-6EE15D1BBEAD
P2860
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Cloning and primary structure ...... ry target of fluoroquinolones.
@en
Cloning and primary structure ...... ry target of fluoroquinolones.
@nl
type
label
Cloning and primary structure ...... ry target of fluoroquinolones.
@en
Cloning and primary structure ...... ry target of fluoroquinolones.
@nl
prefLabel
Cloning and primary structure ...... ry target of fluoroquinolones.
@en
Cloning and primary structure ...... ry target of fluoroquinolones.
@nl
P2093
P2860
P1476
Cloning and primary structure ...... ry target of fluoroquinolones.
@en
P2093
Famechon A
Lagneaux D
P2860
P304
P356
10.1111/J.1365-2958.1994.TB00458.X
P407
P577
1994-08-01T00:00:00Z